Hussman Strategic Advisors Inc. Purchases 2,100 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Hussman Strategic Advisors Inc. increased its position in United Therapeutics Co. (NASDAQ:UTHR) by 33.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,400 shares of the biotechnology company’s stock after acquiring an additional 2,100 shares during the quarter. United Therapeutics comprises about 0.9% of Hussman Strategic Advisors Inc.’s holdings, making the stock its 20th biggest holding. Hussman Strategic Advisors Inc.’s holdings in United Therapeutics were worth $2,964,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC lifted its position in United Therapeutics by 0.8% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,913 shares of the biotechnology company’s stock valued at $1,761,000 after purchasing an additional 39 shares during the last quarter. MBM Wealth Consultants LLC lifted its position in United Therapeutics by 1.9% during the fourth quarter. MBM Wealth Consultants LLC now owns 2,151 shares of the biotechnology company’s stock valued at $775,000 after purchasing an additional 41 shares during the last quarter. Signaturefd LLC lifted its position in United Therapeutics by 8.8% during the third quarter. Signaturefd LLC now owns 633 shares of the biotechnology company’s stock valued at $227,000 after purchasing an additional 51 shares during the last quarter. UMB Bank n.a. lifted its holdings in shares of United Therapeutics by 4.9% in the 4th quarter. UMB Bank n.a. now owns 1,101 shares of the biotechnology company’s stock worth $388,000 after acquiring an additional 51 shares during the last quarter. Finally, MassMutual Private Wealth & Trust FSB lifted its holdings in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 58 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on UTHR shares. The Goldman Sachs Group boosted their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. LADENBURG THALM/SH SH boosted their price objective on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Argus boosted their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Oppenheimer boosted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Finally, UBS Group boosted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $382.08.

United Therapeutics Trading Up 2.1 %

Shares of United Therapeutics stock opened at $380.78 on Thursday. The company’s fifty day simple moving average is $362.58 and its two-hundred day simple moving average is $359.89. The company has a market cap of $17.00 billion, a P/E ratio of 16.72, a PEG ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a 12-month low of $213.75 and a 12-month high of $417.82.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, Director Nilda Mesa sold 255 shares of the business’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $355.77, for a total transaction of $90,721.35. Following the transaction, the director now directly owns 5,528 shares of the company’s stock, valued at approximately $1,966,696.56. The trade was a 4.41 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $372.75, for a total transaction of $3,727,500.00. Following the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $960,576.75. The trade was a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 124,164 shares of company stock valued at $45,398,793. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.